Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
Research
Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, in Preclinical Leukemia Models at the European Hematology Association Congress
WATERTOWN, Mass., June 09, 2023 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degr…
Patient Education Webcasts
Spotlight on Aggressive Non-Hodgkin Lymphomas (NHL)
Research
Immune-Onc Therapeutics Announces IO-202 Granted Fast Track Designation by FDA for the Treatment of Relapsed or Refractory CMML
PALO ALTO, CA, June 7, 2023 – Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage oncology company dedicated to the discovery and …
Patient Education Webcasts
Cafecito con LLS: Hablemos de la salud mental
News
Subaru Partners with The Leukemia & Lymphoma Society for 8th Year to Share Warmth, Love and Relief with Patients Facing Cancer
Subaru of America, Inc. is renewing its partnership with The Leukemia & Lymphoma Society (LLS) during Subaru Loves to Care® month in June. Subaru will…
News
FDA Approves New Bispecific Antibody for Non-Hodgkin Lymphoma Subtype
Epcoritamab gives patients with diffuse large B-cell lymphoma another treatment option.
Research
Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy
Heidelberg, Germany, May 23, 2023 – Affimed N.V. announced today that the U.S. Food and Drug Administration (FDA) has cleared its IND application for …
Patient Education Webcasts
Spotlight on Chronic Lymphocytic Leukemia (CLL)
News
Cancer Drug Shortages Greatly Affect Patients with Blood Cancer, Families Across the US
Leukemia & Lymphoma Society Chief Medical Officer Gwen Nichols, MD, releases statement noting that the LLS continues to advocate for solutions to keep…
News
Immunotherapy Greatly Improves Survival for Infants with an Aggressive Form of Leukemia
These results mark a big step forward in the treatment of infants with this form of Acute Lymphoblastic Leukemia (ALL).
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
